Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astellas Pharma Inc (OP: ALPMY )

16.33 +0.27 (+1.68%)
Streaming Delayed Price Updated: 3:51 PM EDT, Jun 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 71,018
Open 16.57
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 16.06
Today's Range 16.32 - 16.60
52wk Range 12.82 - 16.91
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
Why Shares of Annexon Are Plummeting Thursday
Mixed trial results on a geographic atrophy eye drug led investors to sell the biotech stock. 
Via The Motley Fool

Performance

YTD
+7.29%
+7.29%
1 Month
+7.01%
+7.01%
3 Month
+17.23%
+17.23%
6 Month
+7.65%
+7.65%
1 Year
+4.95%
+4.95%

More News

Read More
Google Launches Tools To Detect Fake Images, Apple May Encounter Delays In iPhone 15 Production, Shake Shack Sees Activist Investor Proxy Fight: Today's Top Stories
Via Benzinga
Astellas' Menopause Drug Under FDA Review
Via Benzinga
Sutro Biopharma Stock Surges On Cancer Treatment Pact
Via Benzinga
Astellas' Menopause Drug Sores FDA Approval, After Regulatory Setback
Via Benzinga
Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move Today
Via The Motley Fool
Pfizer, Astellas' Xtandi Combo Therapy Cuts Risk Of Metastasis, Death In Prostate Cancer By 58%
Via Benzinga
Biotech Buying Bonanza: Iveric Bio Snags $5.9 Billion Deal From Astellas Pharma
Via Investor's Business Daily
First Republic Folds Amid Banking Crisis, Elon Musk Expects Starship To Make Orbit On Next Launch, DOJ Probes Mastercard Over Anti-Competitive Debit-Card Practices: Today's Top Stories
Via Benzinga
Nasdaq, S&P 500 Futures On Edge Over First Republic Failure, Tech Earnings: Analyst Pins Hopes On Fed's Next Move
Via Benzinga
Astellas Pharma Acquires Iveric Bio For $5.9B To Focus On 'Blindness & Regeneration'
Via Benzinga
FDA Approves Merck's Keytruda Combined With Seagen/Astellas's Padcev For Advanced Urothelial Cancer
Via Benzinga
Japanese Government Urges China To Release Astellas Pharma's Employee
Via Benzinga
Pfizer, Astellas Tout Positive Xtandi Data To Potentially Expand Label For The Prostate Cancer Drug
Via Benzinga
Best-Selling Drugs by Bristol Myers, Pfizer, AbbVie Likely Candidates For US Price Negotiation
Via Benzinga
'Here We Go Again': Seagen Soars As Pfizer Reportedly Mulls A Takeover
Via Investor's Business Daily
Analyst Says Selecta Biosciences' Gout Candidate Can Potentially Raise The Bar On Several Fronts
Via Benzinga
Sandoz Acquires Antifungal Agent From Astellas, Reinforcing Hospital Offering
Via Benzinga
Super Bowl Commercials 2023: The Complete List Of Super Bowl LVII Ads And The Companies Behind Them
Via Benzinga
What Is Going on With Taysha Gene (TSHA) Stock Today?
Via InvestorPlace
Astellas Pharma Invests $50M To Support Taysha's Gene Therapy Programs
Via Benzinga
Seagen Shares Jump On Positive Data From Urothelial Cancer Trial
Via Benzinga
7 Best Biotech Stocks to Buy in July 2022
Via InvestorPlace
The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.